COST-EFFECTIVENESS OF ADDING BEDAQUILINE TO BACKGROUND DRUG REGIMENS FOR THE TREATMENT OF MULTIDRUG-RESISTANT AND EXTENSIVELY-RESISTANT TUBERCULOSIS IN ITALY

Author(s)

Codecasa LR1, Toumi M2, D'Ausilio A3, Aiello A3, Da Mele F4, Termini R4, Uglietti A4, Hettle R5, Graziano G6, De Lorenzo S7
1Niguarda Hospital, Milan, Italy, 2Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille, France, 3Creativ Ceutical, Milano, Italy, 4Janssen-Cilag, Cologno Monzese, Italy, 5PAREXEL International, London, UK, 6Policlinico Universitario Paolo Giaccone, Palermo, Italy, 7E. Morelli Hospital ASST, Sondrio, Italy

OBJECTIVES:  To evaluate the cost-effectiveness of adding bedaquiline to a background regimen (BR) of drugs for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in Italy. METHODS:  A cohort-based Markov model was adapted to the Italian Healthcare setting. The model aims to estimate the incremental cost-effectiveness ratio (ICER) of bedaquiline plus BR (BBR) versus BR alone in the treatment of MDR-TB and XDR-TB, over a 10-year time horizon. The costs and effectiveness (life years gained [LYG]) of treatment were evaluated in the base case from both a National Health Service (NHS) and societal perspective. Clinical data were sourced from clinical trials. Resource utilisation data were obtained from interviewing a panel of clinicians. The study considered NHS tariffs for inpatient and outpatient resources and an average hospital stay, with active disease, of 63 days for MDR_TB patients and 76 days for XDR_TB patients according to expert opinion. Drug costs were provided by reference centres for the treatment of tuberculosis. A 3% annual discount rate was applied to costs and effectiveness. Sensitivity analyses were conducted to test the robustness of the results. RESULTS:  Over a 10-year period, the ICERs for BBR versus BR alone were €16,639/LYG and €4,081/LYG for the NHS and societal perspectives, respectively. Similar results were observed across the deterministic sensitivity analysis. BBR dominated BR alone when considering a societal perspective, a 20% price decrease for bedaquiline and a mean hospital stay of 6 months. In the PSA, BBR was cost-effective in 88% - 96% of simulations, at thresholds of €40,000 and €60,000 (NHS perspective). From a societal perspective, BBR was dominant in 19% of simulations, and considered cost-effective in 94%-97% of simulations. CONCLUSIONS:  In Italy, BBR is cost-effective vs BR alone in the treatment of MDR-TB and XDR-TB under a range of scenarios.

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PRS31

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Respiratory-Related Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×